Evidence map›Paper›PMID 30804150›Full record

ArticleIn vivo (Athens, Greece)

Perioperative Management of Antiplatelet Therapy in Patients With History of Coronary Artery Disease Undergoing Surgery for Esophageal Cancer: A Single-center Experience.

Dimitrios Schizas, Nikoletta A Theochari, Christina A Theochari, Damianos G Kokkinidis, Vasileia Domi, Eustratia Mpaili, Anil Kumar Jonnalagadda, Alkistis Kapelouzou, Anargyros Bakopoulos, Theodore Liakakos

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Dimitrios SchizasFirst Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
Nikoletta A TheochariSurgery Working Group, Society of Junior Doctors, Athens, Greece nickyth12@gmail.com.
Christina A TheochariSurgery Working Group, Society of Junior Doctors, Athens, Greece.
Damianos G KokkinidisDepartment of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, U.S.A.
Vasileia DomiThird Department of Surgery, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece.
Eustratia MpailiFirst Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
Anil Kumar JonnalagaddaDepartment of Cardiology, Medstar Washington Hospital Center, Washington, DC, U.S.A.
Alkistis KapelouzouFirst Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
Anargyros BakopoulosThird Department of Surgery, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece.
Theodore LiakakosFirst Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
National and Kapodistrian University of Athens · GRLaiko General Hospital of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo present the experience of the upper Gastrointestinal Unit of the Surgical Department of National and Kapodistrian University of Athens in order to inform surgeons of the exact harms and benefits associated with their decisions concerning management of antiplatelet therapy. MATERIALS AND

methodsThis was a single-center study of patients who underwent surgery for esophageal cancer and had concomitant coronary artery disease from 1/1/2005 to 31/7/2017. Patients were divided into two cohorts based on when their antiplatelet therapy was stopped (<7 vs. ≥7 days). Esophageal cancer was classified as esophageal only or as Siewert type I, II, or III based on tumor location at the gastroesophageal junction. A univariate logistic regression model was developed to assess the relationship between baseline variables and myocardial infraction, mortality, bleeding and stroke after the operation. For all tests, differences with a value of p<0.05 were considered significant.

resultsDuring the study period, 135 esophagectomies were performed for esophageal cancer. Almost 17% of them had concomitant coronary artery disease medically managed with antiplatelet therapy. No difference was found in terms of myocardial infarction, stroke or severe bleeding events between patients that stopped antiplatelet therapy for more or less than 7 days before esophagectomy.

conclusionIt is a reasonable approach to discontinue antiplatelet therapy for more than 7 days before surgery, especially in such a population of patients with esophageal cancer that require complex operations with high bleeding risk.

Indexed as

AgedClopidogrelCoronary Artery DiseaseEsophageal NeoplasmsFemaleHemorrhageHumansMaleMiddle AgedPerioperative CarePlatelet Aggregation InhibitorsRisk AssessmentRisk FactorsStentsTiclopidineClopidogrelPlatelet Aggregation InhibitorsTiclopidineantiplatelet therapycoronary artery diseasecoronary stentsEsophageal cancerpreoperative management

Identifiers

PMID30804150
PMCPMC6506307
OpenAlexW2917715501

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.